Haemonetics Corporation (HAE) |
| 60.48 1.21 (2.04%) 04-14 16:00 |
| Open: | 58.92 |
| High: | 60.54 |
| Low: | 58.86 |
| Volume: | 388,256 |
| Market Cap: | 2,831(M) |
| PE Ratio: | 16.66 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 74.96 |
| Resistance 1: | 64.18 |
| Pivot price: | 57.30 |
| Support 1: | 57.80 |
| Support 2: | 53.86 |
| 52w High: | 87.32 |
| 52w Low: | 47.32 |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
| EPS | 3.630 |
| Book Value | 19.460 |
| PEG Ratio | 0.00 |
| Gross Profit | 17.082 |
| Profit Margin (%) | 13.31 |
| Operating Margin (%) | 21.01 |
| Return on Assets (ttm) | 6.4 |
| Return on Equity (ttm) | 19.3 |
Mon, 13 Apr 2026
A Look at Haemonetics Corp (HAE) After 3.4% Gain -- GF Value $86 - GuruFocus
Wed, 08 Apr 2026
Haemonetics (HAE) Is Up 5.7% After FDA Expands VASCADE MVP XL Labeling for Larger EP Sheaths - simplywall.st
Wed, 08 Apr 2026
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Weakness? - Sahm
Wed, 01 Apr 2026
Haemonetics will post earnings at 6 a.m., then take questions at 8 - Stock Titan
Mon, 30 Mar 2026
FDA expands use of Haemonetics device in atrial fibrillation care - Stock Titan
Thu, 26 Mar 2026
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |